Skip to main content

Advanced Search

Advanced Search

Current Filters

Filter your query

Publication Types



Newsletter Article


Democrats Are Suddenly Eyeing a Valuable Pharma Asset: Its Patents

Forget the push to bring more generics to market or to tweak Medicare’s arcane payment system. Democrats, newly empowered in D.C. and on the hunt for bigger and bolder ways to lower drug prices, are suddenly taking aim at a far more central part of pharma’s monopoly power: the patents the industry holds on its drugs. (Lev Facher, STAT)

Publication Details